Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy L. Burroughs acquired 15,450 shares of Terns Pharmaceuticals stock in a transaction on Thursday, December 5th. The shares were bought at an average cost of $7.15 per share, for a total transaction of $110,467.50. Following the completion of the transaction, the chief executive officer now owns 19,099 shares in the company, valued at approximately $136,557.85. This trade represents a 423.40 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Terns Pharmaceuticals Stock Performance
Shares of NASDAQ TERN opened at $6.58 on Tuesday. The company has a 50 day simple moving average of $6.97 and a two-hundred day simple moving average of $7.53. Terns Pharmaceuticals, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $11.40. The company has a market capitalization of $558.91 million, a price-to-earnings ratio of -5.58 and a beta of -0.36.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.05. On average, analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
liberals FOOLED by Elon’s shocking surprise
From StocksToTrade | Ad
Elon Musk and Donald Trump fooled everyone.
They said it was to “save free speech”...
Or “fix what the liberals broke”...
But it turns out that was all just a smokescreen to hide the TRUTH…
Click here to discover the real reason Elon Musk became buddy-buddy with Trump.
Several equities analysts recently issued reports on TERN shares. BMO Capital Markets reiterated an "outperform" rating and set a $26.00 price target (up previously from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. JMP Securities reissued a "market outperform" rating and issued a $20.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, December 4th. HC Wainwright restated a "neutral" rating and issued a $7.50 target price on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. Finally, Oppenheimer upped their price target on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an "outperform" rating in a research note on Wednesday, December 4th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.30.
Check Out Our Latest Report on TERN
Hedge Funds Weigh In On Terns Pharmaceuticals
Hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. increased its stake in Terns Pharmaceuticals by 0.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,707,515 shares of the company's stock valued at $22,581,000 after purchasing an additional 17,139 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Terns Pharmaceuticals by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,199,006 shares of the company's stock valued at $14,425,000 after acquiring an additional 11,535 shares in the last quarter. Geode Capital Management LLC raised its holdings in Terns Pharmaceuticals by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,479 shares of the company's stock worth $10,072,000 after acquiring an additional 85,617 shares during the last quarter. Bellevue Group AG bought a new position in Terns Pharmaceuticals in the 3rd quarter valued at approximately $8,691,000. Finally, Parkman Healthcare Partners LLC boosted its stake in Terns Pharmaceuticals by 39.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 545,751 shares of the company's stock valued at $4,552,000 after purchasing an additional 155,481 shares during the last quarter. Institutional investors own 98.26% of the company's stock.
Terns Pharmaceuticals Company Profile
(
Get Free Report)
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
